$STSA News
Last published 3y ago
- 3y agoSTSASatsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 65th Annual Scientific MeetingGlobeNewswireDURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101
- 3y agoSTSASatsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of MigraineGlobeNewswireJanuary 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S.
- 3y agoSTSASatsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a
- 3y agoSTSASatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business HighlightsGlobeNewswire- Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects - - Submitted STS101 New Drug
- 3y agoSTSASatsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel
- 3y agoSTSASatsuma Pharmaceuticals Provides STS101 Development Program and Corporate UpdateGlobeNewswireFurther analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important
- 3y agoSTSASatsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel
- 3y agoSTSASatsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of MigraineGlobeNewswireSTS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom STS101 showed superiority (p<0.001) differences versus
- 4y agoSTSASatsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswire- On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 - - $64.4 million in cash, cash equivalents and marketable securities as of September
- 4y agoSTSASatsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety TrialGlobeNewswireSTS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to date Over 8,000 migraine attacks treated with more than 10,000 doses of STS101; of which, over 5,500 migraine attacks treated with more than 6,900 d
- 4y agoSTSASatsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireSouth San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc
- 4y agoSTSASatsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development ProgramGlobeNewswire- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects - - On track to announce SUMMIT trial topline results in Q4 2022 - - Completed STS101 clinical and CMC pre-NDA meetings with FDA -
- 4y agoSTSASatsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of MigraineGlobeNewswire- More than 1,400 subjects randomized -- Satsuma expects to announce topline SUMMIT trial results in Q4 2022 - SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharm
- 4y agoSTSASatsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society's 64th Annual Scientific MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product
- 4y agoSTSASatsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101GlobeNewswireSOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product
- 4y agoSTSASatsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product
- 4y agoSTSAA Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects - NCT05337254ClinicalTrials.govDHE Relative Bioavailability, DHE Comparative Bioavailability, Serious Adverse Events, Treatment-Related Adverse Events
- 4y agoSTSASatsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business HighlightsGlobeNewswire- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash, cash equivalents and marketable securities as of December 31, 2021, provides runway into second half of 202
- 4y agoSTSASatsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc
- 4y agoSTSASatsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product
- 5y agoSTSASatsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of Directors – - $110 million in cash as of September 30, 2021 provides runway into second ha
- 5y agoSTSACyrano Therapeutics Announces the Appointment of John Kollins to its Board of DirectorsPR NewswireDELRAY BEACH, Fla., Nov. 9, 2021 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, today announced that it has appointed biopharmaceutical indu
- 5y agoSTSASatsuma Pharmaceuticals to Present at Upcoming Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product
- 5y agoSTSASatsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product
- 5y agoSTSASatsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc
- 5y agoSTSASatsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc
- 5y agoSTSASatsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of MigraineGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product
- 5y agoSTSAA Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine - NCT04940390ClinicalTrials.govPain Freedom at 2 Hours, Freedom From Most-Bothersome Symptom at 2 Hours
- 5y agoSTSASatsuma Pharmaceuticals to Present at SVB Leerink's CNS ForumGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product
- 5y agoBIOCCLOVHSTOIDRA+1Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?PR NewswireNEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, HSTO, IDRA, STSA, and CLOV. T
- 5y agoACORCLSDNNOXORPH+1Thinking about buying stock in Clearside Biomedical, Acorda Therapeutics, Orphazyme, Nano-X Imaging, or Satsuma Pharmaceuticals?PR NewswireNEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, ACOR, ORPH, NNOX, and STSA. T
- 5y agoSTSASatsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose StrengthsGlobeNewswire- All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile - - Initiating SUMMIT Phase 3 efficacy trial to evaluate STS101 5.2 mg in the acute t
- 5y agoSTSASatsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewswire-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022- -Results expected in Q2 from ongoing Phase 1 trial to inform dose selection for Phase 3- -$133 million in cash, cash
- 5y agoSTSASatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business HighlightsGlobeNewswireAnnounced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022 Closed $80 million private...
- 5y agoSTSASatsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present...
- 5y agoSTSASatsuma Pharmaceuticals Announces Updated STS101 Development PlanGlobeNewswire-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022- -Proceeds from $80 million private placement and existing cash expected to fund...
- 5y agoSTSASatsuma Pharmaceuticals Announces $80 Million Private Placement FinancingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that it has agreed to sell...
- 5y agoSTSASatsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will...
- 6y agoSTSASatsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial ResultsGlobeNewswireAnalysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 Cash, cash equivalents and marketable securities of $82.1 million as of...
- 6y agoSTSASatsuma Pharmaceuticals to to participate in the following November Virtual Investor ConferencesGlobeNewswire- Credit Suisse - 29th Annual Healthcare Conference -November 9th -12th - Stifel 2020 Virtual Healthcare Conference -November 16th -18th SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE)...
- 6y agoSTSASatsuma Pharmaceuticals Announces Topline Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of MigraineGlobeNewswireTopline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two...
- 6y agoSTSASatsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial ResultsGlobeNewswireCompleted treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020Initiated patient...
- 6y agoSTSASatsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101GlobeNewswireASCEND results expected to support STS101 NDA filing in Q4 2021 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage...
- 6y agoSTSASatsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed...
- 6y agoSTSASatsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting Hosted via a Virtual Meeting PlatformGlobeNewswireMeeting Launch date is Saturday, June 13th 2020 at 9:00am (PT) Safety of Dihydroergotamine for the Acute Treatment of Migraine: Reality vs Perception The Efficacy of Dihydroergotamine versus...
- 6y agoSTSASatsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual PlatformGlobeNewswirePharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations Water-insoluble...
- 6y agoSTSASatsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business ResultsGlobeNewswireSTS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020 Company well-capitalized with cash, cash equivalents, and marketable...
- 6y agoSTSASatsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob...
- 6y agoSTSASatsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President...
- 6y agoSTSASatsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face PainGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results...